Advanced Biomaterials for 3D Printed Medtech and Biotech (Premium)

Join us for an exclusive event on Advanced Biomaterials for 3D Printed Medtech and Biotech, where leading experts, innovators, and researchers will explore cutting-edge materials shaping the future of healthcare. From bioresorbable polymers and nanocomposites to cell-compatible hydrogels and innovative scaffolds, this event highlights how advanced biomaterials are driving breakthroughs in medical devices, bioprinting, regenerative medicine, and drug delivery. Perfect for entrepreneurs, clinicians, scientists, and investors, attendees will gain insight into the latest R&D trends, regulatory pathways, and commercialization strategies transforming the medtech and biotech industries through 3D printing.

Speakers:

Janaina Dernowsek

Janaina de Andréa Dernowsek, PhD, is a scientist, entrepreneur, and global leader in the fields of 3D bioprinting, biofabrication, and regenerative medicine. With a doctorate in Genetics, three postdoctoral fellowships in biofabrication, and an MBA in Innovation, Business, and Leadership, she combines deep scientific expertise with strategic vision. As co-founder and CEO of Quantis Biotechnology and BioEdTech, Janaina has been at the forefront of developing human extracellular matrix–based biomaterials and next-generation biofabrication technologies. Her work bridges fundamental biology with advanced engineering, enabling applications in healthcare, aesthetics, and education.

Driven by a mission to transform innovation into impact, Janaina has spent over a decade advancing biofabrication through research, entrepreneurship, and education. She has led pioneering projects on human-derived extracellular matrices, 3D bioprinted tissues, and customized bioprinters, while also training professionals worldwide in hands-on biofabrication methodologies. Recognized for her role in shaping the future of deep tech in health, she actively contributes to international collaborations, scientific dissemination, and the creation of scalable biotech solutions that redefine the boundaries of human health and longevity.

Riccardo Levato

Associate Professor of Translational Bioengineering and Biomaterials at the Department of Clinical Sciences (Faculty of Veterinary Medicine, Utrecht University), and at the Department of Orthopaedics of the University Medical Center Utrecht. Principal Investigator at the Regenerative Medicine Center Utrecht. Prior to moving to Utrecht, he worked in several research groups across Europe: 3Bs, University of Minho (Portugal); BioMatLab, Technical University of Milan (Italy), Institute for Bioengineering of Catalonia (IBEC, Spain), and he holds a cum laude PhD in Biomedical Engineering from IBEC and from the Technical University of Catalonia. Since 2020 he was awarded a Starting grant from the European Research Council on the development of a novel volumetric bioprinting technology for organoid research and to engineer functional bone marrow analogues in vitro. Since 2021, he is coordinator of a European consortium (ENLIGHT, Future and Emerging Technologies scheme, European Innovation Council pilot), aiming at developing biofabricated pancreas to study treatments for diabetes.

He published more than 85 peer-reviewed articles international journals, and he was conferred several awards including the 2016 Wake Forest Institute for Regenerative Medicine Young Investigator Award, the 2021 Jean Leray award from the European Society for Biomaterials, the 2022 Robert Brown award from the Tissue Engineering and Regenerative Medicine International Society, and the 2023 Mid-career Investigator Award from the International Society for Biofabrication (ISBF). Riccardo is also serving on the Board of Directors of ISBF.

Jasper Van Hoorick

Dr. Jasper Van Hoorick, PhD, is the co-founder and Chief Executive Officer of BIO INX, a spin-off from Ghent University and Vrije Universiteit Brussel that specializes in advanced biomaterials and bio-inks for high-resolution 3D bioprinting and biofabrication. With a background in polymer chemistry, he earned recognition for his innovative work early on—receiving the Agoria award in 2014 for his master’s thesis in tissue engineering. His doctoral research, supported by an FWO grant, focused on developing biodegradable polymer materials for ocular tissue regeneration, especially through multiphoton lithography techniques, culminating in a summa cum laude PhD in 2019 and the prestigious Solvay award in 2020 .

Since founding BIO INX in 2022, Jasper has driven the company’s mission to transform the field of regenerative medicine by bridging rigorous academic research with practical, real-world applications. Under his leadership, BIO INX has become a global player in 3D bioprinting, developing bio-inks that not only enable tissue printing at micrometer and nanometer resolution—but which also hold promise for replacing animal testing and, ultimately, printing functional organs.
The company is already pioneering materials for Light-based cell-printing technologies so precise they can reproduce intricate tissue architectures, and is even collaborating on the development of artificial miniature hearts aimed at space-based aging studies. Which explains BIO INX’ slogan: ‘From Light to Life”.

Bowman Bagley

Bowman Bagley is Vice President of Commercial at CollPlant, where he is leading the introduction of recombinant human type I collagen and its methacrylated derivative to the U.S. market for applications in cell culture, tissue engineering, 3D bioprinting, and medical devices. He brings nearly a decade of leadership experience from Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer.

At Advanced BioMatrix, Bowman helped develop and commercialize more than 100 products—including bioinks for extrusion, DLP, 2PP, and volumetric bioprinting—while driving growth across product development, business development, and global sales. He holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah.

Scott Taylor, PhD

Dr. Scott Taylor is the Chief Technology Officer at Poly-Med and specializes in material selection and medical device design. He has worked on development teams for more than twenty marketed medical devices and is experienced in the creation of novel materials and processes, product design and development, advanced manufacturing services, application and development of intellectual property, as well as physical and chemical testing protocols.

Dr. Taylor has undergraduate degrees in physics and mechanical engineering from Furman University and Clemson University, respectively, and completed his doctorate in Bioengineering from Clemson University. Through his tenure, Dr. Taylor has published numerous papers and conference abstracts, several book chapters, and is inventor for more than twenty-five (25) US and international patents. In addition to his position at Poly-Med, he maintains an appointment as adjunct faculty of Bioengineering at Clemson University.

Moderator:

Dr. Jenny Chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.